Korsana Biosciences (KRSA) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Tyra Biosciences (TYRA) over the past year, gaining 90.0% versus a gain of 46.5%. Over five years, TYRA leads with a +22.2% price change compared with -91.1% for KRSA. Korsana Biosciences is the larger company by market cap ($1.53 billion vs $1.37 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | TYRA |
|---|---|---|
| Share price | $33.51 | $19.97 |
| Market cap | $1.53B | $1.37B |
| 1-day change | +6.37% | -2.06% |
| YTD return | +276.94% | -24.04% |
| 1-year return | +89.97% | +46.52% |
| 5-year return | -91.10% | +22.22% |
| EPS (TTM) | $-7.07 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.36 | $40.65 |
| 52-week low | $7.19 | $13.29 |
| Distance from 52-week high | -43.55% | -50.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +31.30% | +137.61% |
| Average volume | 29.26K | 857.13K |
| Shares outstanding | 45.54M | 68.76M |
| Employees | 19 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed TYRA by 43.5 percentage points over the past year.
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
KRSA vs TYRA FAQ
Which is bigger, Korsana Biosciences or Tyra Biosciences?
Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.53B compared with $1.37B for Tyra Biosciences (TYRA).
Which stock has performed better over the past year, KRSA or TYRA?
KRSA returned +89.97% over the past 12 months, compared with +46.52% for TYRA (price return, excluding dividends). Past performance does not predict future results.
Are Korsana Biosciences and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.